These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9462684)

  • 1. Re: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
    Liu WM; te Poele RH; Joel SP
    J Natl Cancer Inst; 1998 Feb; 90(3):246-7. PubMed ID: 9462684
    [No Abstract]   [Full Text] [Related]  

  • 2. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
    Hansen LT; Lundin C; Helleday T; Poulsen HS; Sørensen CS; Petersen LN; Spang-Thomsen M
    Lung Cancer; 2003 May; 40(2):157-64. PubMed ID: 12711116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of topoisomerase II inhibitor, vepesid, on binding of doxorubicin with DNA in tumor cells sensitive to anthracycline].
    Bogush TA; Chmutin EF; Syrkin AB
    Biull Eksp Biol Med; 1997 Jan; 123(1):87-90. PubMed ID: 9213469
    [No Abstract]   [Full Text] [Related]  

  • 4. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.
    Kaplan E; Gündüz U
    Biomed Pharmacother; 2012 Feb; 66(1):29-35. PubMed ID: 22285073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
    Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
    Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
    J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.
    Asano T; An T; Mayes J; Zwelling LA; Kleinerman ES
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):307-13. PubMed ID: 8870683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced DNA ligase activity in etoposide resistant human lymphatic leukaemia CEM cells.
    Fredriksson E; Liliemark E; Polischouk A; Soderhall S; Albertioni F; Ljungquist S
    Biochem Pharmacol; 2002 Jan; 63(2):259-64. PubMed ID: 11841801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
    Lage H; Helmbach H; Dietel M; Schadendorf D
    Br J Cancer; 2000 Jan; 82(2):488-91. PubMed ID: 10646909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multinucleation regulated by the Akt/PTEN signaling pathway is a survival strategy for HepG2 cells.
    Mukherjee A; Misra S; Howlett NG; Karmakar P
    Mutat Res; 2013 Aug; 755(2):135-40. PubMed ID: 23796964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
    Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.